GlassScriptPhysician profile
Hasan Mousli
NPI 1710984679
$8,085.92
in general payments reported to CMS, 2019-2025
39 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,173 · 2020: $794 · 2021: $1,060 · 2022: $823 · 2023: $431 · 2024: $1,008 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009 · Travel and Lodging: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.58 |
| Travel and Lodging | $1,226.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,467.58 | 2020-2025 | |
| Si-Bone, INC. | $1,038.75 | 2025 | |
| Supernus Pharmaceuticals, INC. | $767.07 | 2019-2020 | |
| Genzyme Corporation | $512.82 | 2019-2022 | |
| Stryker Corporation | $391.54 | 2024 | Omnicurve, Augment Injectable |
| Pfizer INC. | $390.84 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $365.38 | 2019-2021 | |
| Ucb, INC. | $327.16 | 2019-2025 | Briviact |
| Amgen INC. | $326.50 | 2019-2022 | |
| Biogen, INC. | $321.00 | 2019-2023 | Tysabri, Vumerity |
| Amneal Pharmaceuticals LLC | $226.35 | 2021-2025 | Crexont, Rytary |
| Lilly USA, LLC | $210.67 | 2019-2024 | Emgality |
| Teva Pharmaceuticals USA, INC. | $186.11 | 2019-2021 | |
| Neurelis, INC. | $183.38 | 2022-2025 | Valtoco |
| Emd Serono, INC. | $134.64 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Mousli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.